Kip 25

Primecap Odyssey Growth Stumbles

Primecap’s return trails the competition as well as the Standard & Poor’s 500-stock index, which returned 9.4%. What gives?

After posting a nearly flawless record since its 2004 inception, Primecap Odyssey Growth (symbol POGRX)—a member of the Kiplinger 25—stumbled over the past 12 months. Primecap’s 1.2% return trails the competition, which gained an average of 9.8% over the same period, and Standard & Poor’s 500-stock index, which returned 9.4%. The fund’s disappointing performance puts it behind 98% of funds that invest in large, growing firms. So, what happened?

Odyssey Growth lagged during the market’s recent downswing and subsequent upswing. Between mid September and late December 2018, the fund fell 23.8%—more than the 19.4% loss in the S&P 500. As the index recovered 16.6% in the first 16 weeks of 2019, the fund managed only a 14.8% return.

Primecap Odyssey tends to hold a healthy slug of assets in go-go health care shares and technology stocks, and that has proved a challenge. In particular, the fund has 32% of its assets invested in health care firms—mostly biotechnology companies. Health care and info tech shares have helped the fund’s performance over the long term, but 2018’s late-fall turbulence “was a forceful example of how quickly trends can reverse,” the firm said in an October report.

A recent drag on the fund has been Biogen (symbol BIIB, a top 25 holding. The biotech firm lost nearly one-third of its value in March, after it abandoned its Alz­heimer’s therapy, which was in late-stage trials. (Biogen still has a strong pipeline of treatments for other neurological diseases, and the stock has recovered a bit since then.)

Five managers divide the fund’s assets and run each part independently. They favor stocks in fast-growing firms that they think the market has underestimated. Cautiously optimistic, the managers expect growth in the U.S. economy and corporate earnings to slow. But in both cases, “solid growth should endure,” they say.

Though Odyssey Growth’s sector concentration can hobble returns at times, over the long haul, the strategy delivers. The fund’s 16.7% annualized return over the past decade beats the S&P 500 by an average of 1.5 percentage points per year and ranks among the top 23% of all large-growth funds.

Most Popular

Where's My Refund? How to Track Your Tax Refund Status
tax refunds

Where's My Refund? How to Track Your Tax Refund Status

If you're waiting for your tax refund, the IRS has an online tool that lets you track the status of your payment.
March 2, 2021
Where's My Stimulus Check? Use the IRS's "Get My Payment" Portal to Get an Answer
Coronavirus and Your Money

Where's My Stimulus Check? Use the IRS's "Get My Payment" Portal to Get an Answer

The IRS has an online tool that lets you track the status of your stimulus checks.
February 19, 2021
Your Guide to Roth Conversions
Special Report
Tax Breaks

Your Guide to Roth Conversions

A Kiplinger Special Report
February 25, 2021

Recommended

T. Rowe Price Financial Services Banks on a Turnaround
Stock Market Today

T. Rowe Price Financial Services Banks on a Turnaround

This fund is a good way to bet on an economic rebound.
February 24, 2021
DSTL: A Value Fund With a Twist
Becoming an Investor

DSTL: A Value Fund With a Twist

The fund’s 51.3% return since its inception in 2018 has more than tripled that of traditional value funds.
February 24, 2021
2 Top-Tier T. Rowe Price Mutual Funds
mutual funds

2 Top-Tier T. Rowe Price Mutual Funds

T. Rowe Price's mutual funds typically stand out among their peers, but these two selections provide elite equity and bond exposure for this point in …
February 24, 2021
Earth-First Funds Are Soaring
Markets

Earth-First Funds Are Soaring

Funds with sustainability in mind are super popular these days; these six are ready to deliver returns.
February 24, 2021